StockData
Replimune Group, Inc. logo

Replimune Group, Inc. (REPL) stock

REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.69−1.72 (-8.03%)

Close on Nov 17, 2026Market cap $1.87BP/E –Yield –

Replimune free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Replimune's free cash flow for the twelve months ending Sep 30, 2026 was -$245.77M. For fiscal 2026 it was -$284.57M. The highest annual figure on record is -$7.32M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$284.57M–
FY2025Mar 31, 2025-$198.94M–
FY2024Mar 31, 2024-$191.13M–
FY2023Mar 31, 2023-$130.32M–
FY2022Mar 31, 2022-$84.52M–
FY2021Mar 31, 2021-$63.78M–
FY2020Mar 31, 2020-$67.09M–
FY2019Mar 31, 2019-$27.98M–
FY2018Mar 31, 2018-$16.15M–
FY2017Mar 31, 2017-$7.32M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2027CQ3 2026Sep 30, 2026-$47.78M–
Q1 FY2027CQ2 2026Jun 30, 2026-$75.73M–
Q4 FY2026CQ1 2026Mar 31, 2026-$56.17M–
Q3 FY2026CQ4 2025Dec 31, 2025-$66.09M–
Q2 FY2026CQ3 2025Sep 30, 2025-$82.56M–
Q1 FY2026CQ2 2025Jun 30, 2025-$79.76M–
Q4 FY2025CQ1 2025Mar 31, 2025-$54.87M–
Q3 FY2025CQ4 2024Dec 31, 2024-$52.51M–
Q2 FY2025CQ3 2024Sep 30, 2024-$40.72M–
Q1 FY2025CQ2 2024Jun 30, 2024-$50.84M–
Q4 FY2024CQ1 2024Mar 31, 2024-$47.91M–
Q3 FY2024CQ4 2023Dec 31, 2023-$48.84M–
Q2 FY2024CQ3 2023Sep 30, 2023-$45.34M–
Q1 FY2024CQ2 2023Jun 30, 2023-$49.04M–
Q4 FY2023CQ1 2023Mar 31, 2023-$33.05M–
Q3 FY2023CQ4 2022Dec 31, 2022-$29.14M–
Q2 FY2023CQ3 2022Sep 30, 2022-$33.61M–
Q1 FY2023CQ2 2022Jun 30, 2022-$34.52M–
Q4 FY2022CQ1 2022Mar 31, 2022-$23.71M–
Q3 FY2022CQ4 2021Dec 31, 2021-$18.81M–
Q2 FY2022CQ3 2021Sep 30, 2021-$23.39M–
Q1 FY2022CQ2 2021Jun 30, 2021-$18.61M–
Q4 FY2021CQ1 2021Mar 31, 2021-$16.90M–
Q3 FY2021CQ4 2020Dec 31, 2020-$13.61M–
Q2 FY2021CQ3 2020Sep 30, 2020-$17.25M–
Q1 FY2021CQ2 2020Jun 30, 2020-$16.02M–
Q4 FY2020CQ1 2020Mar 31, 2020-$12.60M–
Q3 FY2020CQ4 2019Dec 31, 2019-$19.79M–
Q2 FY2020CQ3 2019Sep 30, 2019-$20.76M–
Q1 FY2020CQ2 2019Jun 30, 2019-$13.94M–
Q4 FY2019CQ1 2019Mar 31, 2019-$7.88M–
Q3 FY2019CQ4 2018Dec 31, 2018-$6.74M–
Q2 FY2019CQ3 2018Sep 30, 2018-$6.39M–
Q1 FY2019CQ2 2018Jun 30, 2018-$6.98M–
Q4 FY2018CQ1 2018Mar 31, 2018-$4.23M–
Q3 FY2018CQ4 2017Dec 31, 2017-$2.70M–
Q2 FY2018CQ3 2017Sep 30, 2017-$3.69M–
Q1 FY2018CQ2 2017Jun 30, 2017-$5.53M–

More Replimune figures

See a number that looks wrong?